X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The commercial stage pharmaceutical company focused on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol) confirmed to investors that the TGA has registered Feraccru® as a treatment in the Australian Register of Therapeutic Goods.
Lead Product(s): Ferric Maltol
Therapeutic Area: Hematology Product Name: Feraccru
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
PT20 is a novel iron-based phosphate binder that has the potential to treat patients with hyperphosphatemia (when there is too much phosphorus present in the blood) related to dialysis or non-dialysis dependent chronic kidney disease (CKD).
Lead Product(s): Ferric oxide adipate
Therapeutic Area: Nephrology Product Name: PT20
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 16, 2020
Details:
Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .
Lead Product(s): Ferric Maltol
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical
Deal Size: $62.8 million Upfront Cash: $11.4 million
Deal Type: Licensing Agreement January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
